Lonza virtual Symposium, hosted by the MassBioHub

Digitally delivered | Tuesday 27 October 2020

Gain insight and discuss the challenges of early stage biopharmaceutical development

Lonza and the MassBioHub are pleased to invite you to join us for a complimentary virtual symposium to gain insight from experts in the different approaches and techniques to successfully progress biotherapeutic candidates from discovery to the clinic. Hear about updates on enhancements to new and established technologies enabling translational research. The day includes talks from industry experts, local biotech companies and technical specialists from Lonza.

Our networking breaks and virtual lunch offers the opportunity to speak with fellow scientists, presenters and Lonza specialists. During the symposium, you will have the opportunity to book a 1-on-1 consultation session with our scientific experts to be held in the days following the symposia.



Attendance at this event is complimentary for biotechs developing biopharmaceuticals and by invitation only. For more information, including the latest agenda and to register:

Register Here

Insight and discussion with our experts

Agenda (Eastern Standard Time)

08.30 am – 08.45 am Welcome and overview of symposium
Kendalle Burlin O'Connell | COO MassBio
Moderator: Dr. Hari Kumar | Pharmaceutical Executive, Independent Board Member, former CEO Adheron Therapeutics
08.45 am – 09.20 am Keynote presentation
Dr. Robert Langer | Institute Professor, MIT Langer Research Laboratories
09.20 am – 9.45 am Local company presentation
9:45 am – 10.20 am

Early developability assessment tools – Successful de-risking strategies to support progression of biologics from discovery to development
Dr. Yvette Stallwood | Head of Applied Protein Services, Lonza

10.20 am – 10.35 am Virtual networking
10.35 – 11.05 am An approach for successful tech transfers of pre-IND programs to CDMOs
Matt Wallace | Senior Director of CMC Operations, Jounce Therapeutics
11.05 am – 11.55 am
Approaches to maximize successful development of cell lines expressing a diverse range of proteins
Dr. Alison Porter | Head of Expression System Sciences, Lonza
11.55 am – 12.10 pm
Virtual networking
12.10 pm – 12.35 pm
Stelexis Therapeutics
Dr. Patrick Doyle | CEO
12.35 pm – 1.05 pm
A multiplex approach for generating a potent autologous adoptive cellular immunotherapy for treating cancer
Dr. Frank Borriello | Founder & CEO, Alloplex Biotherapeutics, Inc.
1.05 pm – 1.10 pm
Wrap up and end of symposia

For more information, including the latest agenda and to register:

Register Here

This event is complementary for biotechs developing biopharmaceuticals and by invitation only.